Stock Code
688016.SH
Stock Code
688016.SH
Technology Innovation, People Centric
Adhering to the mission of providing trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives, Endovastec™ is committed to building a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.
Products
Endovastec™ focuses on the research and development (R&D), manufacturing, sales and services of aortic, peripheral vascular and tumor intervention devices,and our main products are thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, drug-coated balloon dilatation catheters, balloon dilatation catheters, vena cava filters and snare retrieval kits etc.
News
 (3).png)
Endovastec™ Shines at ESVS & ASVS 2026, Connecting the World Through Innovation and Advancing the Future of Aortic Disease Treatment
In October 2026, Endovastec™ participated in two leading international vascular surgery events, the European Society for Vascular Surgery Annual Meeting (ESVS 2026) and the Congress of the Asian Society for Vascular Surgery (ASVS 2026). Through product exhibitions, academic exchange, clinical experience sharing, and discussions on real-world data, Endovastec™ showcased its innovative achievements and total solutions in aortic intervention, further strengthening its global presence and influence within the international vascular community.
20 Oct 2026
 副本 (3).png)
Endovastec™’s Aorfix™ Endograft System Granted NMPA Green Channel Designation for Innovative Medical Devices
Shanghai, China – August 27, 2026–MicroPort® Endovastec™ announced that the Aorfix™ AAA Endovascular Stent Graft with IntelliFlex™ Low Profile Delivery System (“Aorfix™”), developed by its European subsidiary Lombard Medical Ltd. (Lombard Medical), has been granted access to China’s National Medical Products Administration (NMPA) Green Channel, a special review pathway for innovative medical devices. This marks the eleventh product from Endovastec™ to receive this designation.
27 Aug 2026
Endovastec™ Announces Interim Results for 2026: Advancing Innovation and Global Expansion
On August 26, 2026, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™, SSE: 688016) announced the interim results of Endovastec™ and its subsidiaries (the Company) for the six months ended June 30, 2026 (the Reporting Period). During the Reporting Period, the Company achieved revenue of RMB 794 million, with a net profit attributable to shareholders of listed companies of RMB 322 million and basic earnings per share of RMB 2.67. The Company expects to distribute total cash dividends of RMB 157 million (tax inclusive), representing a cash dividend of RMB 13 per 10 shares (tax inclusive).
26 Aug 2026
About us
News
Products
Investor Relations
Telephone:(86) (21) 38139300
Address:Building #1,3399 Kangxin Rd., SIMZ Century Medicine Park, Shanghai201318,P.R. China
Fax:(86) (21) 33750026
©Copyright 2012-2026, Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd.
Internet Drug Information Service Qualification Certificate No.: (Hu) - Non-operating -2024-0188
Website record/ license No.：沪ICP备14048493号-1 
HGWA Bei No.31011502014536
The registered trademarks of “微创", "MicroPort" and"
" are registered trademarks of Shanghai MicroPort Medical (Group) Co., Ltd., they have been authorized to be used by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., and no other party shall use such trademarks without prior written permission thereof.
